Steroid-responsive pancreatitides

Table 1 Clinical presentations of steroid responsive pancreatitides

Acute pancreatitis	Chronic pancreatitis
Acute or subacute forms of IgG4 RD-AP	IgG4 related disease pancreatitis
Idiopathic duct centric pancreatitis	Idiopathic duct centric chronic pancreatitis
ICI-related pancreatitis
VasC-related pancreatitis

AP: Acute pancreatitis; ICIs: Immune checkpoint inhibitors; IgG4-RD: IgG4-related disease.

Table 2 Immune checkpoint inhibitors

Immune checkpoint inhibitors
Cytotoxic T lymphocyte antigen-4	Ipilimumab
Programmed death-1 inhibitor	Nivolumab, pembrolizumab
Programmed death ligand-1 inhibitor	Atezolizumab, avelumab, durvalumab

Table 3 Modified from reference 98 Common Terminology Criteria for Adverse Events v4.03 from April 2011 through April 2018

Modified adverse events according to common terminology criteria for adverse events
Grade 1	Mild	Asymptomatic or mild symptoms; clinical or diagnostic observations only
Grade 2	Moderate	Enzyme elevation or radiologic findings only; minimal, local or noninvasive intervention indicated
Grade 3	Severe	Lipase elevation > 2 times normal (60 U/L), severe pain, vomiting, needing medical intervention; hospitalization or prolongation of hospitalization indicated
Grade 4	Life-threatening consequences	Urgent intervention indicated
Grade 5	Death	Death related to adverse events

CTCAE: Common terminology criteria for adverse events.